Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.

[1]  P. Durrington.  Hyperlipidaemia : diagnosis and management , 1995 .

[2]  C. Abbott,et al.  The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. , 1993, The Biochemical journal.

[3]  D. Steinberg,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.

[4]  J P Kane,et al.  Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Hamsten,et al.  Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man , 1992, The Lancet.

[6]  D. Sullivan,et al.  Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. , 1992, Biochemical pharmacology.

[7]  V. Ord,et al.  Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. , 1992, The American journal of pathology.

[8]  Carolyn A. Converse,et al.  Lipoprotein analysis : a practical approach , 1992 .

[9]  A. J. Valente,et al.  Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.

[10]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[11]  P. Winocour,et al.  Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. , 1991, Atherosclerosis.

[12]  K. Widhalm,et al.  Precipitation with polyethylene glycol and density-gradient ultracentrifugation compared for determining high-density lipoprotein subclasses HDL2 and HDL3. , 1991, Clinical chemistry.

[13]  A. Smolen,et al.  PURIFICATION OF HUMAN SERUM PARAOXONASE/ARYLESTERASE , 1991 .

[14]  A. Smolen,et al.  Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[15]  L. Fong,et al.  High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. , 1990, Biochimica et biophysica acta.

[16]  R. D. Cohen.  The metabolic and molecular basis of acquired disease , 1990 .

[17]  Y. Morino,et al.  Protective effect of lipoproteins containing apoprotein A‐I on Cu2+ ‐ catalyzed oxidation of human low density lipoprotein , 1989, FEBS letters.

[18]  U. Steinbrecher,et al.  Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. , 1989, The Journal of biological chemistry.

[19]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[20]  H. Esterbauer,et al.  A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. , 1989, Journal of lipid research.

[21]  M. Mackness.  'A'-esterases. Enzymes looking for a role? , 1989, Biochemical pharmacology.

[22]  C. Walker,et al.  Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. , 1986, Clinical chemistry.

[23]  S. Eisenberg,et al.  High density lipoprotein metabolism. , 1984, Journal of lipid research.

[24]  G. Chisolm,et al.  LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. , 1979, Atherosclerosis.

[25]  A. Main.  The differentiation of the A-type esterases in sheep serum. , 1960, The Biochemical journal.